Eli Lilly and Company (NYSE:LLY) Position Increased by Western Wealth Management LLC

Western Wealth Management LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 11.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 10,444 shares of the company’s stock after acquiring an additional 1,110 shares during the period. Western Wealth Management LLC’s holdings in Eli Lilly and Company were worth $6,088,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Obermeyer Wood Investment Counsel Lllp grew its position in shares of Eli Lilly and Company by 3.1% during the fourth quarter. Obermeyer Wood Investment Counsel Lllp now owns 755 shares of the company’s stock worth $440,000 after acquiring an additional 23 shares during the last quarter. Xponance Inc. grew its position in Eli Lilly and Company by 0.9% in the 4th quarter. Xponance Inc. now owns 191,009 shares of the company’s stock valued at $111,343,000 after buying an additional 1,718 shares in the last quarter. AIA Group Ltd grew its position in Eli Lilly and Company by 2.7% in the 4th quarter. AIA Group Ltd now owns 17,719 shares of the company’s stock valued at $10,329,000 after buying an additional 467 shares in the last quarter. Cambridge Trust Co. grew its position in Eli Lilly and Company by 0.7% in the 4th quarter. Cambridge Trust Co. now owns 10,930 shares of the company’s stock valued at $6,371,000 after buying an additional 78 shares in the last quarter. Finally, Oliver Lagore Vanvalin Investment Group lifted its holdings in Eli Lilly and Company by 27.7% in the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 387 shares of the company’s stock valued at $226,000 after acquiring an additional 84 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on LLY. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Barclays upped their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a report on Friday, March 15th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a report on Monday. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.

Insider Buying and Selling at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Down 0.6 %

NYSE:LLY traded down $4.82 on Thursday, hitting $745.95. 1,715,622 shares of the company’s stock traded hands, compared to its average volume of 3,067,708. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 1 year low of $367.35 and a 1 year high of $800.78. The firm has a 50-day moving average price of $764.03 and a 200-day moving average price of $657.67. The company has a market cap of $708.77 billion, a PE ratio of 129.32, a price-to-earnings-growth ratio of 1.63 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter in the previous year, the business posted $2.09 EPS. The business’s revenue for the quarter was up 28.1% on a year-over-year basis. Equities analysts anticipate that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.